Study aims to Fine-Tune infection shield for myeloma patients
NCT ID NCT07094048
Summary
This study aims to find the best level of protective antibodies to give patients with hard-to-treat multiple myeloma who are receiving a new type of immunotherapy. The new treatment can weaken the immune system, raising the risk of serious infections. Researchers are comparing whether aiming for a lower level of antibodies is just as safe and effective at preventing infections as the current standard higher level.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA REFRACTORY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Intégré de Cancérologie
RECRUITINGQuébec, Quebec, Canada
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.